Protagenic Therapeutics, Inc.\new Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Protagenic Therapeutics, Inc.\new (PTIX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.73 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2025-03-31
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $1.73.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $1.21, a 78.39% decline year-over-year.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-03-31 was $5.60, a 220.00% increase year-over-year.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-03-31 was $1.75, a 75.00% increase year-over-year.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $1.73.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $4.84, a 74.63% decline from fiscal 2021.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $19.08, a 990.29% increase from fiscal 2020.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $1.75, a 52.17% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $1.73 10-K · filed 2025-03-31 | ||||
| 2024-09-30 | $1.73 10-Q · filed 2024-11-14 | ||||
| 2024-06-30 | $1.73 10-Q · filed 2024-08-14 | ||||
| 2024-03-31 | $1.73 10-Q · filed 2024-05-15 | ||||
| 2022-12-31 | $4.84 10-K/A · filed 2024-05-14 | ||||
| 2022-09-30 | $1.21 10-Q · filed 2022-11-14 | ||||
| 2022-06-30 | $1.21 10-Q · filed 2022-08-11 | ||||
| 2022-03-31 | $1.21 10-Q · filed 2022-05-13 | ||||
| 2021-12-31 | $19.08 10-K · filed 2023-03-31 | $4.77 10-K · filed 2022-04-07 | |||
| 2021-09-30 | $4.77 10-Q · filed 2021-11-15 | ||||
| 2021-06-30 | $4.96 10-Q · filed 2021-08-16 | ||||
| 2021-03-31 | $5.60 10-Q · filed 2021-05-17 | ||||
| 2020-12-31 | $1.75 10-K · filed 2021-03-25 | ||||
| 2020-09-30 | $1.75 10-Q · filed 2020-11-16 | ||||
| 2020-06-30 | $1.75 10-Q · filed 2020-08-14 | ||||
| 2020-03-31 | $1.75 10-Q · filed 2020-06-18 | ||||
| 2019-12-31 | $1.15 10-K · filed 2021-03-25 | ||||
| 2019-09-30 | $1.15 10-Q · filed 2019-11-14 | ||||
| 2019-06-30 | $1.15 10-Q · filed 2019-08-14 | ||||
| 2019-03-31 | $1.00 10-Q · filed 2019-05-16 | ||||
| 2018-12-31 | $1.75 10-K · filed 2020-04-29 | ||||
| 2018-09-30 | $1.75 10-Q · filed 2018-11-08 | ||||
| 2018-06-30 | $1.75 10-Q · filed 2018-08-14 | ||||
| 2018-03-31 | $1.75 10-Q · filed 2018-05-15 | ||||
| 2017-12-31 | $1.68 10-K · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |